Oya, Yuko
Yoshida, Tatsuya http://orcid.org/0000-0002-4962-2957
Asada, Kazuhiro
Oguri, Tetsuya
Inui, Naoki
Morikawa, Sayako
Ito, Kentaro
Kimura, Tomoki
Kunii, Eiji
Matsui, Takashi
Kubo, Akihito
Kato, Tatsuo
Abe, Takashi
Tsuda, Takeshi
Hida, Toyoaki
Funding for this research was provided by:
Boehringer Ingelheim
Aichi Cancer Research Foundation
Article History
Received: 19 August 2020
Accepted: 28 December 2020
First Online: 12 January 2021
Ethics approval and consent to participate
: This study was conducted in accordance with the principles expressed in the Declaration of Helsinki. The full protocol was approved by the institutional review board in each institution. All participants in the study arm provided written informed consent before enrollment.
: Not applicable.
: Dr. Yoshida has obtained research grants from Nippon Boehringer Ingelheim. Dr. Hida has obtained research grants from Novartis Pharma, Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Janssen Pharmaceutical, and Astellas, and has received personal fees from Novartis Pharma, Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, and Pfizer. Dr. Ito has obtained personal fees from Nippon Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical. All the other authors have no conflicts of interest. Dr. Ogutri has obtained research grant from Nippon Boehringer Ingelheim and speaker’s bureau from Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Eli Lilly. Dr. Kimura has obtained speaker’s bureau from Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Novartis Pharma, Meiji Seika Pharmaceutical, MSD, Kyorin Pharmaceutical, Ono Pharmaceutical. Dr. Kubo has obtained honoraria from Boehringer Ingelheim.